Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Zhang, Di MD a; Ke, Li MD a; Ni, Zhen MD a; Chen, Yu PhD a; Zhang, Lin-Hui MD a; Zhu, Shao-Hua MD a; Li, Chan-Juan PhD b; Shang, Lei PhD b; Liang, Jie PhD a; Shi, Yong-Quan PhD a,*
96(32):e7697, August 2017.
(Format: HTML, PDF)
Background: Due to increasing antimicrobial resistance, a bismuth-based quadruple regimen has been recommended as an alternative first-line therapy for Helicobacter pylori (H pylori) eradication. However, different results are varied greatly and the availability of bismuth was limited in some countries. We assessed the efficacy and safety of 14-day berberine-containing quadruple therapy as an alternative regimen for H pylori eradication.
Methods: In a randomized, open-label, non-inferiority, phase IV trial between November 25, 2014, and October 15, 2015, 612 treatment-naive patients were randomly assigned to 14-day berberine-containing (n = 308) or 14-day bismuth-containing (n = 304) quadruple therapy. The primary outcomes were eradication rates determined by the 13C urea breath test (13C-UBT) 28 days after the end of treatment. The secondary outcomes were adverse events and compliance.
Results: The baseline demographic data including age, gender, body mass index (BMI), general condition and severity score were not statistically different in both groups. The eradication rates in bismuth and berberine groups were 86.4% (266/308) and 90.1% (274/304) in intention-to-treat (ITT) analysis (P = .149), and 89.6% (266/297) and 91.3% (273/299) in per-protocol (PP) analysis (P = .470), respectively. No statistically significant difference was found in the overall incidence of adverse events between both groups (35.7% vs 28.6%, P = .060).
Conclusions: Both regimens achieved the recommended efficacy for H pylori eradication. The berberine-containing quadruple regimen was not inferior to bismuth-containing quadruple regimen and can be recommended as an alternative regimen for H pylori eradication in the local region.
Copyright (C) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.